[go: up one dir, main page]

ECSP088105A - Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparación y su aplicación en terapéutica - Google Patents

Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparación y su aplicación en terapéutica

Info

Publication number
ECSP088105A
ECSP088105A EC2008008105A ECSP088105A ECSP088105A EC SP088105 A ECSP088105 A EC SP088105A EC 2008008105 A EC2008008105 A EC 2008008105A EC SP088105 A ECSP088105 A EC SP088105A EC SP088105 A ECSP088105 A EC SP088105A
Authority
EC
Ecuador
Prior art keywords
group
pyrrolo
aryl
alkylene
alkyl
Prior art date
Application number
EC2008008105A
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Andre Malanda
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP088105A publication Critical patent/ECSP088105A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)

Abstract

La invención se refiere a los compuestos de fórmula general (I) : en la que n es igual a 0, 1 , 2 ó 3 ; el núcleo pirrolopiridina es un grupo pirrolo[3,2-b]piridina, un grupo pirrolo[3,2-c]piridina, un grupo pirrolo[2,3-c]piridina o un grupo pirrolo[2,3-b]piridina; estando el núcleo pirrolopiridina opcionalmente sustituido en posición carbonada 4, 5, 6 y/o 7 con uno o varios sustituyentes X, idénticos o difernetes uno del otro ; Z1, Z2, Z3, Z4 y Z5 representan, independientemente uno del otro, un átomo de hidrógeno o de halógeno o un grupo alquilo-C1-C6, cicloalquilo-C3-C7, cicloalquilo-C3-C7-alquileno-C1-C3, fluoroalquilo-C1-C6, alcoxilo-C1-C6, fluoroalcoxilo-C1-C6, ciano, C(O)NR1R2, nitro, NR1R2, tioalquilo-C1-C6, -S(O)-alquilo-C1-C6, - S(O)2-alquilo-C1-C6, SO2NR1R2, NR3COR4, NR3SO2R5 , arilo-alquileno-C1-C6 o arilo, estando el arilo y arilo-alquileno-C1-C6 opcionalmente sustituidos; W representa un grupo bicíclico fusionado de fórmula : unido al átomo de nitrógeno por las posiciones 1, 2, 3 ó 4 ; A representa un heterociclo opcionalmente sustituido de 5 a 7 eslabones que comprende de uno a tres heteroátomos elegidos entre O, S o N ; en el estado de base o de sal de adición a un ácido, así como en el estado de hidrato o de solvato. Procedimiento de preparación y aplicación en terapéutica.
EC2008008105A 2005-07-22 2008-01-14 Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparación y su aplicación en terapéutica ECSP088105A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0507804A FR2888848B1 (fr) 2005-07-22 2005-07-22 Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
PCT/FR2006/001767 WO2007010138A2 (fr) 2005-07-22 2006-07-19 Derives de ν-(arylalkyl)-1h-pyrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ECSP088105A true ECSP088105A (es) 2008-02-20

Family

ID=36039505

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008105A ECSP088105A (es) 2005-07-22 2008-01-14 Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparación y su aplicación en terapéutica

Country Status (35)

Country Link
US (2) US7763636B2 (es)
EP (1) EP1912644B1 (es)
JP (1) JP4938012B2 (es)
KR (1) KR101257969B1 (es)
CN (1) CN101247808B (es)
AR (1) AR057668A1 (es)
AT (1) ATE451923T1 (es)
AU (1) AU2006271518B2 (es)
BR (1) BRPI0614066A2 (es)
CA (1) CA2615676C (es)
CR (1) CR9643A (es)
CY (1) CY1109891T1 (es)
DE (1) DE602006011170D1 (es)
DK (1) DK1912644T3 (es)
EA (1) EA013747B1 (es)
EC (1) ECSP088105A (es)
ES (1) ES2338363T3 (es)
FR (1) FR2888848B1 (es)
HR (1) HRP20100150T1 (es)
IL (1) IL188520A (es)
MA (1) MA29617B1 (es)
MX (1) MX2008001018A (es)
MY (1) MY145062A (es)
NI (1) NI200800021A (es)
NO (1) NO20080394L (es)
NZ (1) NZ564870A (es)
PL (1) PL1912644T3 (es)
PT (1) PT1912644E (es)
RS (1) RS51233B (es)
SI (1) SI1912644T1 (es)
TN (1) TNSN07485A1 (es)
TW (1) TWI386407B (es)
UA (1) UA93881C2 (es)
WO (1) WO2007010138A2 (es)
ZA (1) ZA200800439B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888847B1 (fr) 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
FR2911605B1 (fr) * 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
JP5580735B2 (ja) * 2007-06-12 2014-08-27 ジェネンテック, インコーポレイテッド N−置換アザインドール類及び使用方法
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
GB0915892D0 (en) * 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
GB201913756D0 (en) * 2019-09-24 2019-11-06 Chromatwist Ltd Contrast agent
US20230137893A1 (en) * 2020-02-05 2023-05-04 The Rockefeller University PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
TW200403223A (en) * 2002-02-15 2004-03-01 Glaxo Group Ltd Novel compounds
JP2004091480A (ja) * 2002-07-11 2004-03-25 Takeda Chem Ind Ltd ピロロピリジン誘導体およびその用途
AU2003281044A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Pyrrolopyridine derivative and use thereof
JP4909068B2 (ja) * 2003-02-14 2012-04-04 グラクソ グループ リミテッド カルボキサミド誘導体
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
FR2888848B1 (fr) 2007-09-28
JP2009502766A (ja) 2009-01-29
CA2615676C (fr) 2013-10-15
MY145062A (en) 2011-12-15
RS51233B (sr) 2010-12-31
PL1912644T3 (pl) 2010-06-30
IL188520A (en) 2012-10-31
US20080125459A1 (en) 2008-05-29
CA2615676A1 (fr) 2007-01-25
CR9643A (es) 2008-02-20
KR101257969B1 (ko) 2013-04-24
TNSN07485A1 (fr) 2009-03-17
FR2888848A1 (fr) 2007-01-26
NI200800021A (es) 2010-02-15
DK1912644T3 (da) 2010-05-03
ES2338363T3 (es) 2010-05-06
AR057668A1 (es) 2007-12-12
TWI386407B (zh) 2013-02-21
MA29617B1 (fr) 2008-07-01
EP1912644B1 (fr) 2009-12-16
ATE451923T1 (de) 2010-01-15
EP1912644A2 (fr) 2008-04-23
HRP20100150T1 (hr) 2010-04-30
MX2008001018A (es) 2008-03-14
PT1912644E (pt) 2010-03-17
EA013747B1 (ru) 2010-06-30
TW200728303A (en) 2007-08-01
US20100249183A1 (en) 2010-09-30
AU2006271518A1 (en) 2007-01-25
NO20080394L (no) 2008-03-14
SI1912644T1 (sl) 2010-04-30
CY1109891T1 (el) 2014-09-10
NZ564870A (en) 2010-12-24
EA200800402A1 (ru) 2008-08-29
KR20080027865A (ko) 2008-03-28
ZA200800439B (en) 2009-04-29
US7763636B2 (en) 2010-07-27
AU2006271518B2 (en) 2012-03-01
WO2007010138A3 (fr) 2007-04-12
JP4938012B2 (ja) 2012-05-23
BRPI0614066A2 (pt) 2011-03-09
CN101247808A (zh) 2008-08-20
DE602006011170D1 (de) 2010-01-28
WO2007010138A2 (fr) 2007-01-25
IL188520A0 (en) 2008-04-13
UA93881C2 (en) 2011-03-25
CN101247808B (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
ECSP088105A (es) Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparación y su aplicación en terapéutica
DOP2010000215A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica
ECSP088084A (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
PA8786101A1 (es) "DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA"
PA8764301A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamidas, su preparacion y su aplicacion en terapeutica
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
CY1110232T1 (el) Παραγωγα 2-αρυλ-6-φαινυλ-ιμιδαζο[1,2-α]πυριδιν, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
NI201000124A (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
CL2009000127A1 (es) Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1.
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
ECSP077215A (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
ECSP099216A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BRPI0508072A (pt) derivados de piperidinilalquicarbamatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah
CR9499A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR056418A1 (es) Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR041968A1 (es) Compuestos derivados de imidazol como ligandos del receptor de adenosina
CO6331309A2 (es) Derivados 6-heterociclico-imidazo[1,2-alfa]piridina-2-carboxamidas su preparacion y su aplicacion en terapeutica
ES2194692T3 (es) Derivados de dihidro-furo-(3,4-b)-quinolein-1-onas, su procedimiento de preparacion y las composiciones farmceuticas que los contienen.
WO2008107543A3 (fr) Derives de pyrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
CO6251362A2 (es) Derivados de n-heteroaril-carboxamidas triciclicas su preparacion y su aplicacion en la terapeutica
AR044362A1 (es) Derivados de 6,7 dimetoxi isoquinolinas, inhibidores de gfta, compuestos, procedimiento, composicion farmaceutica y usos
AR062743A1 (es) Esteres de nitrato de aminoalcoholes